Xilio Therapeutics, Inc. (XLO)
Data as of , from SEC Form 4 filings.
See up to 3 months of XLO. The 7-day demo opens the 1M and 3M ranges and puts XLO on your watchlist.
Start 7-day demoLatest XLO insider trades
About Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
- WALTHAM, MA
- 76
- 2021
- XNAS
XLO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 105,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
XLO insider transactions (Form 4)
8222 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Yariv Houvras - Officer | Grant or award | Stock Option (right to buy) | 105,000 | $0.00 | - | |
| Akintunde Olatokumbo Bello | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| James Samuel Shannon | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
 Daniel J. Curran | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Yuan Xu | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
 Robert W. Ross | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Sara Bonstein | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Aoife Brennan | Grant or award | Stock Option (right to buy) | 5,000 | $0.00 | - | |
| Cheryl R. Blanchard | Grant or award | Stock Option (right to buy) | 10,000 | $0.00 | - | |
| James Samuel Shannon | Open-market purchase | Common Stock | 5,000 | $8.79 footnote F1 | $44K | |
| ||||||
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Prefunded Warrants (right to buy) | 3,739,000 | $0.53 | $2.00M | |
| Katarina Luptakova - Officer | Option exercise | Common Stock | 16,625 | - | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 451,885 | $0.00 | - | |
| Katarina Luptakova - Officer | Option exercise | Restricted Stock Units | 16,625 | $0.00 | - | |
| Kevin M. Brennan - Officer | Option exercise | Common Stock | 5,000 | - | - | |
| Kevin M. Brennan - Officer | Open-market sale | Common Stock | 1,826 | $0.64 | $1K | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 95,221 | $0.00 | - | |
| Kevin M. Brennan - Officer | Option exercise | Restricted Stock Units | 5,000 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Option exercise | Common Stock | 19,375 | - | - | |
| Christopher James Frankenfield - Officer | Open-market sale | Common Stock | 7,030 | $0.64 | $5K | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 668,789 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Option exercise | Restricted Stock Units | 19,375 | $0.00 | - | |
| Rene Russo - Officer | Option exercise | Common Stock | 44,250 | - | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 1,500,258 | $0.00 | - | |
| Rene Russo - Officer | Option exercise | Restricted Stock Units | 44,250 | $0.00 | - | |
| GILEAD SCIENCES, INC. - 10% Owner | Other | Prefunded Warrants (right to buy) | 13,335,000 | $0.75 footnote F1 | $10.00M | |
| GILEAD SCIENCES, INC. - 10% Owner | Other | Series B Warrants (right to buy) | 13,335,000 | $0.00 | - | |
| ||||||
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 131,700 | $0.00 | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 55,000 | - footnote F4 | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 55,000 | - footnote F4 | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 25,000 | - footnote F4 | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 25,000 | - footnote F4 | - | |
| Kevin M. Brennan - Officer | Derivative | Stock Option (right to buy) | 20,000 | - footnote F4 | - | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 20,000 | - footnote F4 | - | |
| ||||||
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 625,000 | $0.00 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 44,210 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 44,210 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 15,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 15,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 35,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 35,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 25,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 25,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Derivative | Stock Option (right to buy) | 106,000 | - footnote F4 | - | |
| Katarina Luptakova - Officer | Grant or award | Stock Option (right to buy) | 106,000 | - footnote F4 | - | |
| ||||||
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 925,000 | $0.00 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 155,090 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 155,090 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 23,786 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 23,786 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 37,296 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 37,296 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 45,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 45,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 20,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 20,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 117,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 117,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 150,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 150,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Derivative | Stock Option (right to buy) | 300,000 | - footnote F4 | - | |
| Christopher James Frankenfield - Officer | Grant or award | Stock Option (right to buy) | 300,000 | - footnote F4 | - | |
| ||||||
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 2,075,000 | $0.00 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 239,703 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 239,703 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 473,334 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 473,334 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 135,134 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 135,134 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 50,041 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 50,041 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 100,000 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 100,000 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 150,000 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 150,000 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 350,000 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 350,000 | - footnote F4 | - | |
| Rene Russo - Officer | Derivative | Stock Option (right to buy) | 700,000 | - footnote F4 | - | |
| Rene Russo - Officer | Grant or award | Stock Option (right to buy) | 700,000 | - footnote F4 | - | |
| ||||||
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Common Stock | 1,759,978 | $1.04 | $1.83M | |
| GILEAD SCIENCES, INC. - 10% Owner | Open-market purchase | Prefunded Warrants (right to buy) | 6,092,816 | $1.04 | $6.34M | |
| Kevin M. Brennan - Officer | Grant or award | Stock Option (right to buy) | 26,000 | $0.00 | - | |
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Item 2.02, 9.01
Item 5.02, 9.01
XLO insider trading FAQ
What is the latest insider trade for XLO?
Xilio Therapeutics, Inc. (XLO) had 1 insider filing in the last 90 days, with the most recent on 2026-10-02. The full record for XLO runs to 22 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying XLO stock?
No insider purchases of XLO were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling XLO stock?
No insider sales of XLO were filed in the last 90 days. 2 sales are on record for this company.
Where can I see XLO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects XLO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Yariv Houvras view on EDGAR
- - Akintunde Olatokumbo Bello view on EDGAR
- - James Samuel Shannon view on EDGAR
- - Daniel J. Curran view on EDGAR
- - Yuan Xu view on EDGAR
- - Robert W. Ross view on EDGAR
- - Sara Bonstein view on EDGAR
- - Aoife Brennan view on EDGAR
- - Cheryl R. Blanchard view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where XLO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow XLO with a 7-day demo
- XLO on your watchlist
- Every XLO Form 4 filing on record
- Up to 3 months of XLO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
